July 28, 2016
Pernix Therapeutics Holdings (Morristown, NJ) has announced a reorganization of its senior management team, with John Sedor assuming the role of Chief Executive Officer.
The company also appointed Graham Miao as President and Chief Financial Officer, while reporting that Sanjay Patel, Chief Financial Officer, Terence Novak, Chief Operating Officer, and Barry Siegel, Senior Vice President and General Counsel are no longer employed by Pernix.
John Sedor has served as Pernix's interim CEO and Chairman of the Board since May. Prior to this, he served as President, CEO and Director of Cangene Corporation and President, CEO and Director of CPEX Pharmaceuticals.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.